TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36501004
Drug: 392 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 392 mg/day of blackcurrant powder (low blackcurrant, BC, group, n = 16)
Study: 36501004
Drug: 784 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 784 mg/day of blackcurrant powder (high BC group, n = 11)
Study: 34185664
Drug: Mucoadhesive tablet
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mucoadhesive tablet without the active ingredient
Study: 32977777
Drug: Surgical conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical conditions (treatment)
Study: 34373362
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (sodium alginate)
Study: 32406989
Drug: Standard recommendation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard recommendation on oral rehydration solution use
Study: 34915725
Drug: Group Interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Interpersonal Psychotherapy (IPT-G)
Study: 32912218
Drug: Usual discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual discharge care and monthly social call
Study: 34473302
Drug: Higher kidney
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher kidney injury molecule‐1 (KIM-1)
Study: 33826436
Drug: IOPTx™ system
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOPTx™ system (wearable electroceutical treatment)
Study: 39215063
Drug: 7.5 g
Normalized name: glucose 15 GM per 37.5 GM Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 g of milk chocolate
Study: 34739635
Drug: Molecular-based recommended
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular-based recommended therapy (MBRT) proposed after molecular profiling
Study: 34739635
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of MBRT
Study: 33673567
Drug: Received caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Received caffeine (3 mg/kg)
Study: 33673567
Drug: Placebo (cellulose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose, 3 mg/kg)
Study: 38829619
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (CC)
Study: 34313619
Drug: Methylphenidate (short-acting,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (short-acting, twice daily)
Study: 32900564
Drug: Celecoxib 400
Normalized name: celecoxib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400 mg 2 hours after TKA, followed by 200 mg 6 hours later
Study: 32900564
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 400 mg of celecoxib the second day after surgery
Study: 33785496
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection
Study: 34286867
Drug: Laser-assisted scaling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-assisted scaling and root planing (L-SRP)
Study: 32551725
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy
Study: 34801917
Drug: Midodrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (10 mg every 8 hours)
Study: 34170908
Drug: IV furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV furosemide infusion
Study: 34170908
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV placebo infusion
Study: 32907500
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg donafenib
Study: 32907500
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg donafenib
Study: 34106357
Drug: Pivotal Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal Response Treatment (PRT)
Study: 35569283
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (n = 149)
Study: 35569283
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (n = 151)
Study: 32167038
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of oral cholera vaccine (OCV)
Study: 38729426
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: 33977284
Drug: RTB101 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTB101 10 mg once daily
Study: 33977284
Drug: RTB101 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTB101 10 mg in combination with everolimus 0.1 mg once daily
Study: 34662695
Drug: Tomatis sound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomatis sound therapy (TST)
Study: 35305913
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol 1 g infusion
Study: 35613998
Drug: SBRT (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT (8 Gy x 3 fractions) plus systemic therapy
Study: 37596449
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy alone
Study: 35696837
Drug: Verbal-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal-based cognitive behavioral group therapy (VB-CBGT)
Study: 35124183
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years
Study: 33382352
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of omega-3 supplementation
Study: 32486840
Drug: Guideline-concordant antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant antibiotics (amoxicillin and azithromycin)
Study: 36114901
Drug: Denosumab treatment
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab treatment
Study: 34045222
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of PGA therapy
Study: 34045222
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of PGA therapy after cataract surgery (CPGA)
Study: 33745587
Drug: Micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplementation protocol in Rotterdam: commercial vitamins and trace elements via 8-hour infusion and electrolytes continuously over 24 hours.
Study: 35777921
Drug: InSpace implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: InSpace implant
Study: 34571624
Drug: Ologen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ologen implant
Study: 34750705
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray in sitting position (Group A)
Study: 34750705
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray in supine position (Group B)
Study: 33814231
Drug: 3-dose 20
Normalized name: Hep A, ped/adol, 3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose 20 μg recombinant hepatitis B vaccine
Study: 33814231
Drug: 3-dose 60
Normalized name: Hep A, ped/adol, 3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dose 60 μg recombinant hepatitis B vaccine
Study: 34563277
Drug: Matrix-M-adjuvanted quadrivalent
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix-M-adjuvanted quadrivalent nanoparticle influenza vaccine (qNIV)
Study: 32057673
Drug: Low-dose HCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HCG from Day 7 until at least three follicles reached 17 mm or more
Study: 32057673
Drug: Conventional ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ovarian stimulation with highly purified HMG injections
Study: 616119287
Drug: Retixoft (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retixoft (300 mg alpha-lipoic acid, 1.1 mg vitamin B1, 1.4 mg vitamin B2, 25 mg rutoside) for 3 months
Study: 34672925
Drug: Augmented Reality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Reality Exposure Therapy (ARET)
Study: 38448081
Drug: Direct Oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct Oral Anticoagulants (DOACs)
Study: 38199288
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 μg
Study: 35264104
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment without stimulation.
Study: 32838539
Drug: Telehealth cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth cognitive behavioral therapy for insomnia (CBT‐CI)
Study: 37352528
Drug: Neoadjuvant intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant intensity modulated radiation therapy (18 Gy with fractionated doses of 3 Gy) followed by surgery 4 weeks later
Study: 33808137
Drug: Wrist stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist stabilization exercise + taping therapy (WSE + TT)
Study: 33525659
Drug: Biological control
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological control
Study: 36862472
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine
Study: 33121372
Drug: FF/UMEC/VI 100/62.5/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI 100/62.5/25 µg
Study: 33676601
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg once every 3 weeks for 35 cycles
Study: 32548677
Drug: Subcutaneous Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Immunotherapy (SCIT)
Study: 33819508
Drug: Subcutaneous Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)
Study: 36882015
Drug: Sublingual Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Immunotherapy (SLIT)
Study: 35226081
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oxaliplatin (SOX) - 130 mg/m2 oxaliplatin on day 1 and 80 to 120 mg/d S-1 orally daily for 2 weeks, 6 cycles (2-4 preoperative and 2-4 postoperative)
Study: 35226081
Drug: Fluorouracil, leucovorin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil, leucovorin, and oxaliplatin (FOLFOX) - 130 mg/m2 oxaliplatin, 400 mg/m2 fluorouracil, 400 mg/m2 leucovorin, and 2400 mg/m2 fluorouracil as 46-hour infusion on day 1, 6 cycles (2-4 preoperative and 2-4 postoperative)
Study: 33484775
Drug: Elafibranor 120
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elafibranor 120 mg
Study: 32110986
Drug: 140 mg
Normalized name: caffeine 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg of Zynamite® combined with 140 mg of quercetin
Study: 38300408
Drug: Brodalumab 210
Normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 210 mg
Study: 33285745
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus Pirfenidone capsule
Study: 35397798
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide at a dose of 800 μg twice a day plus usual care
Study: 35107023
Drug: TLR4 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR4 neutralizing antibodies
Study: 32958702
Drug: Lenalidomide concurrent
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide concurrent with PCV13 vaccine (arm A)
Study: 32958702
Drug: Lenalidomide sequential
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide sequential to PCV13 vaccine (arm B)
Study: 35384387
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone (100 mg)
Study: 32673037
Drug: Transdiagnostic behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic behavior therapy (TBT)
Study: 35297288
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (standard treatment)
Study: 37497816
Drug: Compression therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression therapy alone
Study: 33977560
Drug: Varenicline doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline doses (0.25 mg per day, 0.25 mg b.i.d., 0.5 mg b.i.d., and 1.0 mg b.i.d.)
Study: 38554938
Drug: Tildrakizumab 100
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tildrakizumab 100 mg
Study: 36206950
Drug: Initial conservative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial conservative management with GDMT alone and angiography reserved for failure of medical therapy
Study: 33797063
Drug: Bafiertam™ (MMF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bafiertam™ (MMF) 190 mg as 2 × 95 mg delayed-release capsules
Study: 34350569
Drug: Potassium (K)
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium (K) at 11.6 mmol L‐1
Study: 34350569
Drug: Cadmium (Cd)
Normalized name: cadmium
DrugBank: Cadmium (DB14085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadmium (Cd) at 1.5 mmol L‐1
Study: 33785077
Drug: Exergaming (stepping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exergaming (stepping exergame program, 8 weeks, 3 times weekly, 15 min per session)
Study: 35536764
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 or 80 mg, based on sUA at Week 2)
Study: 34622721
Drug: Propolis (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (250 mg/two times per day for three months)
Study: 33860579
Drug: Taxane/platinum therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane/platinum therapy (paclitaxel + carboplatin)
Study: 33860579
Drug: Taxane/platinum therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane/platinum therapy (paclitaxel + carboplatin) with additional docetaxel and nedaplatin
Study: 38847412
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg
Study: 35691323
Drug: Ustekinumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (6 mg/kg IV on day 0, then 90 mg SC every 8 weeks)
Study: 35691323
Drug: Adalimumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160 mg on day 0, 80 mg at 2 weeks, then 40 mg SC every 2 weeks)
Study: 36008759
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg/kg/h continuous infusion (group D2)
Study: 36008759
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg over 10 min and 0.5 μg/kg/h continuous infusion (group D3)
Study: 32000820
Drug: Oral dydrogesterone
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dydrogesterone 10 mg three times daily
Study: 33630863
Drug: Stockholm3 Model
Normalized name: Stockholm tar
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stockholm3 Model (S3M) test as a reflex test for PSA ≥ 2 ng/mL
Study: 33630863
Drug: Stockholm3 Model
Normalized name: Stockholm tar
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stockholm3 Model (S3M) test with reflex thresholds of 1 ng/mL
Study: 34816601
Drug: Motivational Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational Enhancement Therapy (MET) pretreatment to Dialectical Behaviour Therapy Skills Training (DBT-ST); 4-week group MET pretreatment followed by 12-week DBT-ST
Study: 34816601
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy Skills Training (DBT-ST) only; 12-week DBT-ST
Study: 33170417
Drug: Meropenem (MEPM)
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem (MEPM) at 120 mg/kg/day as a 1-h drip infusion 3 times a day
Study: 33170417
Drug: Piperacillin/tazobactam (PIPC/TAZ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (PIPC/TAZ) at 360 mg/kg/day as a 1-h drip infusion 4 times a day
Study: 35129469
Drug: N-Acetyl-Cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-Acetyl-Cysteine (NAC) 1200 mg twice-daily for up to 5 days postoperatively
Study: 35101523
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin (6 mg) prior to IV ketamine (0.5 mg/kg)
Study: 34069369
Drug: Smart-ring CC
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart-ring CC feedback
Study: 35964909
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg, oral, once a day)
Study: 35964909
Drug: Placebo (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral, once a day)
Study: 37865896
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/d)
Study: 32476255
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg)
Study: 32476255
Drug: glimepiride (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride (1 mg)
Study: 36944357
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg daily
Study: 33826539
Drug: High-sensitivity CRP
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity CRP ≥2 mg/dL
Study: 33387165
Drug: Study without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study without Stress (Cognitive Behavioural Therapy program)
Study: 35964947
Drug: Low-flow anesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anesthesia (Group L)
Study: 35964947
Drug: Low-flow anesthesia
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow anesthesia (Group L) in smokers
Study: 32546490
Drug: Amoxicillin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (750 mg three times daily for 100 days)
Study: 36498611
Drug: RA.DI.CA splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: RA.DI.CA splint therapy
Study: 37711718
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of caffeine
Study: 35366092
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of cellulose (placebo)
Study: 36123011
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg once daily for 24 months
Study: 32354234
Drug: Cognitive Flexibility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Flexibility in Aphasia Therapy (CFAT)
Study: 36250371
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (multi-strain probiotics including Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium breve, Bifidobacterium lactis, Bifidobacterium longum, Streptococcus thermophilus) for 8 weeks.
Study: 36037565
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 700 mg xylitol (CG)
Study: 36856614
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once daily
Study: 36457207
Drug: Innovator brand
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovator brand itraconazole 100 mg twice a day for 4 weeks
Study: 33709937
Drug: Web-based therapist-supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based therapist-supported cognitive behavioral therapy (Heart RCT)
Study: 33764654
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (0.25 mg/kg/dose)
Study: 33764654
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (0.5 mg/kg/dose)
Study: 35696440
Drug: Multicomponent intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent intervention including physician training in risk-based treatment, subsidized losartan-HCTZ single-pill combination medications, nurse training in motivational conversations, and telephone follow-ups.
Study: 33009489
Drug: Enzalutamide -
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide - 160 mg/day
Study: 36342811
Drug: Lianhua Qingwen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhua Qingwen capsule (LH), 4 capsules, thrice daily for 14 days
Study: 32646266
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment (Texas Medication Algorithm Project)
Study: 32907282
Drug: Anti-HBs <2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-HBs <2.5 mIU/ml
Study: 33836974
Drug: Palbociclib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (150 mg on days 5 to 18) and T-DM1 (day 1 intravenous) in 21-day treatment cycles
Study: 38458371
Drug: Ticagrelor monotherapy
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor monotherapy
Study: 34000088
Drug: Conventional dual-antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dual-antiplatelet therapy (DAPT)
Study: 38838501
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy